Antibody responses to intradermal recombinant hepatitis B immunization among HIV-positive subjects.
We conducted a randomized, controlled clinical trial to determine the immunogenicity of intradermal immunization with recombinant hepatitis B vaccine among HIV-positive subjects. Induction of antibody concentration over 10 IU/L or four-fold increase in the antibody concentration against hepatitis B surface antigen was regarded a successful immunization. Intradermal immunization induced protective immunity in 39% of participants who received three doses of recombinant hepatitis B vaccine. Intradermal immunization may provide a way to improve the outcome of hepatitis B vaccination among HIV-infected persons. Three doses of intradermal immunization alone induces protective immunity against hepatitis B as often as intramuscular immunization.
Ristola
Matti A
MA
Department of Medicine, Division of Infectious Diseases, Helsinki University Central Hospital, PO Box 348, FIN-00029 HUS Helsinki, Finland. matti.ristola@hus.fi
Vuola
Jenni M
JM
Valle
Martti
M
von Reyn
C Fordham
CF
D000328:Adult; D006679:HIV Seropositivity / Q000276:immunology*; D006509:Hepatitis B / Q000517:prevention & control*; D006510:Hepatitis B Antibodies / Q000096:biosynthesis; D017325:Hepatitis B Vaccines / Q000276:immunology*; D006801:Humans; D007114:Immunization; D007271:Injections, Intradermal; D008297:Male; D014614:Vaccines, Synthetic / Q000008:administration & dosage / Q000627:therapeutic use; D014761:Viral Hepatitis Vaccines / Q000008:administration & dosage / Q000276:immunology*
D006510:Hepatitis B Antibodies; D017325:Hepatitis B Vaccines; D014614:Vaccines, Synthetic; D014761:Viral Hepatitis Vaccines